Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory filings indicated that Nvidia had sold its entire stake in the company.
The giant semiconductor company abandoned its previous stake of 7.71 million shares in Recursion Pharmaceuticals, which is making a name for itself by leveraging artificial intelligence to accelerate and improve drug discovery. NVIDIA had held its stake in the company for two years and was seen as a vote of confidence in the AI-driven approach to drug discovery.
Recursion Pharmaceuticals has expanded its end-to-end AI drug discovery platform by integrating clinical data to support patient translation. Last year, it unveiled a whole-genome map comprising 46 million images of microglial cells to facilitate the identification of new targets.
On February 18, Recursion announced that it will share business updates and report fourth-quarter and full-year 2025 results on February 25.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a “TechBio” company that uses artificial intelligence (AI), machine learning and high-performance automation to accelerate drug discovery, with the goal of reducing the high failure rates and costs of traditional drug development. It operates a proprietary AI-powered platform called Recursion Operating System.
While we recognize the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 11 High-Growth Industrial Stocks to Buy and 10 Best Emerging Markets Stocks to Buy Right Now.
Disclosure: None. This article was originally published in Internal jumpsuit.